Connect with us

Health

Biocon’s Indian subsidiary set to launch its own version of Wegovy, clinical trial anticipated in the coming year

Published

on

India's Biocon developing its own version of Wegovy, clinical trial likely next year, ET HealthWorld

In the race to tap into the booming weight-loss drug market, Indian pharmaceutical company Biocon is developing its own version of Novo Nordisk’s popular drug Wegovy. CEO Siddharth Mittal revealed that the company is willing to conduct a clinical trial next year if necessary to enter the market early. The global market for obesity treatments is expected to exceed $100 billion by the end of the decade, and Biocon is strategically positioning itself to capitalize on this trend.

Biocon, based in Bengaluru, plans to first launch generic versions of weight-loss drugs in emerging markets such as Brazil, Mexico, and Saudi Arabia before venturing into India. The company is aiming to develop a version of semaglutide, the active ingredient in Wegovy and Ozempic, as well as tirzepatide, the main component in Eli Lilly’s rival treatment Mounjaro and Zepbound.

To expedite its entry into the market, Biocon is seeking a waiver on clinical trials from Indian regulators and is exploring partnerships with local manufacturers to ensure a seamless supply chain. The company’s robust research and development investment in generics, with a significant focus on peptides for weight-loss drugs, positions it to compete with other Indian pharmaceutical companies like Dr. Reddy’s and Cipla.

Both Novo Nordisk and Eli Lilly have struggled to meet the high demand for their obesity treatments, with Wegovy and Mounjaro delivering impressive weight loss results in clinical trials. These medications, known as GLP-1 receptor agonists, help regulate blood sugar levels and curb appetite, making them appealing options for individuals struggling with obesity. Biocon’s version of Novo’s Saxenda has already received approval in the UK and is awaiting clearance in Europe and India, signaling the company’s commitment to expanding its presence in the weight-loss drug market.

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Trending